Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 5/20 | 0.44 |
| ▸ | MAOA | P21397 | 4/20 | 0.44 |
| ▸ | IL2 | P60568 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 4/20 | 0.43 |
| ▸ | MMP2 | P08253 | 4/20 | 0.43 |
| ▸ | MMP9 | P14780 | 4/20 | 0.43 |
| ▸ | SLC6A19 | Q695T7 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5034914 | 1.00 | MEN1 (0.50) | MEN1KMT2ANPC1RAB9AHPSE | |
| SCHEMBL5030667 | 0.90 | MEN1 (0.46) | MEN1KMT2ARAB9AHPSEIL2 | |
| SCHEMBL5030663 | 0.90 | MEN1 (0.46) | MEN1KMT2ARAB9AHPSEIL2 | |
| SCHEMBL5030705 | 0.90 | EGFR (0.51) | MEN1KMT2ANPC1RAB9AHPSE | |
| SCHEMBL8227769 | 0.90 | EGFR (0.51) | MEN1KMT2ANPC1RAB9AHPSE | |
| SCHEMBL5030695 | 0.90 | EGFR (0.51) | MEN1KMT2ANPC1RAB9AHPSE | |
| SCHEMBL5030740 | 0.89 | MEN1 (0.54) | MEN1KMT2ANPC1RAB9AMAOB | |
| SCHEMBL5030743 | 0.89 | MEN1 (0.54) | MEN1KMT2ANPC1RAB9AMAOB | |
| SCHEMBL5028544 | 0.86 | MEN1 (0.51) | MEN1KMT2ANPC1RAB9ATRPV1 | |
| SCHEMBL5028542 | 0.86 | MEN1 (0.51) | MEN1KMT2ANPC1RAB9ATRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1998612-A2 | SUBSTITUTED BIARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2008-12-10 | — | — | EP | claimed |
| US-20070254363-A1 | Substituted biaryl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-01 | — | — | US | claimed |
| WO-2007087442-A2 | SUBSTITUTED BIARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-08-02 | — | — | WO | claimed |
| US-20140121217-A1 | SUBSTITUTED BIARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-05-01 | — | — | US | disclosed |
| US-20140121217-A1 | SUBSTITUTED BIARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-05-01 | — | — | US | disclosed |
| US-8623871-B2 | Substituted biaryl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8623871-B2 | Substituted biaryl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8623871-B2 | Substituted biaryl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2014-01-07 | — | — | US | disclosed |
| EP-1998612-A2 | SUBSTITUTED BIARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2008-12-10 | — | — | EP | disclosed |
| US-20070254363-A1 | Substituted biaryl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254363-A1 | Substituted biaryl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254363-A1 | Substituted biaryl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-01 | — | — | US | disclosed |
| WO-2007087442-A2 | SUBSTITUTED BIARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254363-A1 | Substituted biaryl compounds for inflammation and immune-related uses | CCR1, CCR3, CXCR2 | MEN1 4237/4885KMT2A 2650/4885NPC1 477/4885 |
| US-20140121217-A1 | SUBSTITUTED BIARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CCR1, CCR3, CXCR2 | MEN1 4237/4885KMT2A 2650/4885NPC1 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.